Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant adenovirus-p53 SCH-58500
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Phase II Study of SCH 58500 Plus Combination Chemotherapy in Patients with Non-Small Cell Lung Cancer (Summary Last Modified 11/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C/I97-076
Phase I Study of Gene Therapy With SCH-58500 (rAd/p53) Via Hepatic Artery Infusion in Patients With Primary and Metastatic Malignant Tumors of the Liver (Summary Last Modified 07/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C95-063-01, NCI-V97-1179
Phase I Study in Patients with Cutaneous or Subcutaneous, Recurrent Breast Carcinoma or Melanoma Using SCH-58500 (rAd/p53) Administered by Single Intratumoral Dose (Summary Last Modified 08/97)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-I/C95-082-01, NCI-V97-1180
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C95084, SPRI-I/C95-084, NCI-V97-1181, NCT00002960
Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 12/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-I/C95-177-01, NCI-V97-1182
Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection in Patients With Non-Small Cell Lung Cancer (Summary Last Modified 12/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-I95-178-02, NCI-V97-1186
Phase I Study of SCH-58500 (Adenoviral p53 Gene Therapy) in Patients with Recurrent or Progressive Resectable Glioblastoma Multiforme, Anaplastic Astrocytoma, or Anaplastic Mixed Glioma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9703, JHOC-NABTT-9703, NCT00004080
Start Over